Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 3Phase EARLY_PHASE1 2Phase 4 2Phase NA 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Insulin Resistance 2Polycystic Ovary Syndrome 1Diabetes Mellitus, Type 2 1Carotid Intimal Medial Thickness 1 1

Interventions

Zoledronic Acid 28Saline Solution 26Metformin 25Dexamethasone 25Cyclophosphamide 23Cytarabine 22Bupivacaine 20Sodium Chloride 18Vincristine 17Methotrexate 17Letrozole 17Propofol 15Morphine 15Doxorubicin 15Cisplatin 15Prednisolone 14Docetaxel 14Dexmedetomidine 14Bevacizumab 14Oxycodone 13Imiquimod 13Fentanyl 13Capecitabine 13Rituximab 12Mercaptopurine 12Fluorouracil 12Granulocyte Colony-Stimulating Factor 11Everolimus 11Asparaginase 11Acetaminophen 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × Pioglitazone × Clear all
NCT01223196 2016-01-11

PIO-TACE

The University of Texas Health Science Center at San Antonio

Phase 4 Completed
60 enrolled 8 charts

Diabetes Mellitus, Type 2, Insulin Resistance

NCT00145340 2008-09-26

Pioglitazone Treatment in Polycystic Ovary Syndrome

Odense University Hospital

Phase 4 Completed
30 enrolled

Carotid Intimal Medial Thickness 1, Insulin Resistance, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡